Physician profile
Andreas K Klein
NPI 1285740969
$50,992.31
in general payments reported to CMS, 2019-2025
20 companies · $26.56 in 2025
The $26.56 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,775 · 2021: $208 · 2022: $238 · 2023: $30K · 2024: $6,994 · 2025: $26.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,250.00 |
| Food and Beverage | $687.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21,625.00 | 2023-2024 | |
| Eli Lilly and Company | $13,025.00 | 2023 | |
| Verastem, INC. | $10,556.25 | 2019 | |
| Kite Pharma, INC. | $2,844.31 | 2020-2024 | Yescarta |
| Novartis Pharma Ag | $1,723.51 | 2023-2024 | Kymriah |
| Novartis Pharmaceuticals Corporation | $938.19 | 2019-2023 | Kymriah |
| Beigene USA, INC. | $84.79 | 2022 | |
| Acrotech Biopharma INC. | $83.96 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $69.81 | 2023 | |
| Glaxosmithkline, LLC. | $26.56 | 2025 | Ojjaara |
| Amgen INC. | $14.93 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.